WO1999007736A3 - Lipoprotein-regulating medicaments - Google Patents

Lipoprotein-regulating medicaments Download PDF

Info

Publication number
WO1999007736A3
WO1999007736A3 PCT/IB1998/001256 IB9801256W WO9907736A3 WO 1999007736 A3 WO1999007736 A3 WO 1999007736A3 IB 9801256 W IB9801256 W IB 9801256W WO 9907736 A3 WO9907736 A3 WO 9907736A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipoprotein
regulating medicaments
medicaments
regulating
lsr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1998/001256
Other languages
French (fr)
Other versions
WO1999007736A2 (en
Inventor
Bernard Bihain
Lydie Bougueleret
Frances Yen-Potin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Merck Biodevelopment SAS
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9710088A external-priority patent/FR2767136B1/en
Priority to EP98936610A priority Critical patent/EP1003783B1/en
Priority to DK98936610T priority patent/DK1003783T3/en
Priority to US09/485,316 priority patent/US6344441B1/en
Priority to AU85563/98A priority patent/AU754942B2/en
Priority to CA002298849A priority patent/CA2298849A1/en
Priority to DE69838720T priority patent/DE69838720T2/en
Priority to JP2000506238A priority patent/JP2001512746A/en
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Genset SA filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of WO1999007736A2 publication Critical patent/WO1999007736A2/en
Publication of WO1999007736A3 publication Critical patent/WO1999007736A3/en
Anticipated expiration legal-status Critical
Priority to US10/060,845 priority patent/US6946444B2/en
Priority to US10/072,159 priority patent/US7220722B2/en
Priority to US11/741,979 priority patent/US20080249009A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods and pharmaceutical compositions useful for modulating lipoprotein levels in vivo. The invention stems from the discovery that activity of the Lipolysis Stimulated Receptor (LSR) can be inhibited or enhanced by exogenous agents, including polypeptides.
PCT/IB1998/001256 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments Ceased WO1999007736A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP98936610A EP1003783B1 (en) 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments
DK98936610T DK1003783T3 (en) 1997-08-06 1998-08-06 Lipoprotein regulatory drugs
US09/485,316 US6344441B1 (en) 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments
AU85563/98A AU754942B2 (en) 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments
CA002298849A CA2298849A1 (en) 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments
DE69838720T DE69838720T2 (en) 1997-08-06 1998-08-06 LIPOPROTEIN-REGULATORY MEDICAMENTS
JP2000506238A JP2001512746A (en) 1997-08-06 1998-08-06 Drug for lipoprotein regulation
US10/060,845 US6946444B2 (en) 1997-08-06 2002-01-29 Lipoprotein-regulating medicaments
US10/072,159 US7220722B2 (en) 1997-08-06 2002-02-05 Lipoprotein-regulating medicants
US11/741,979 US20080249009A1 (en) 1997-08-06 2007-04-30 Lipoprotein-Regulating Medicaments

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9710088A FR2767136B1 (en) 1997-08-06 1997-08-06 LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATIONS TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND ASSOCIATED RISKS OR COMPLICATIONS
FR97/10088 1997-08-06
FR98/05032 1998-04-22
FR9805032A FR2767135B1 (en) 1997-08-06 1998-04-22 LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09/485,316 A-371-Of-International US6344441B1 (en) 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments
US09485316 A-371-Of-International 1998-08-06
US10/060,845 Division US6946444B2 (en) 1997-08-06 2002-01-29 Lipoprotein-regulating medicaments
US10/072,159 Division US7220722B2 (en) 1997-08-06 2002-02-05 Lipoprotein-regulating medicants

Publications (2)

Publication Number Publication Date
WO1999007736A2 WO1999007736A2 (en) 1999-02-18
WO1999007736A3 true WO1999007736A3 (en) 1999-05-20

Family

ID=26233732

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB1998/001257 Ceased WO1999007737A2 (en) 1997-08-06 1998-08-06 Lsr receptor, cloning and uses
PCT/IB1998/001256 Ceased WO1999007736A2 (en) 1997-08-06 1998-08-06 Lipoprotein-regulating medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001257 Ceased WO1999007737A2 (en) 1997-08-06 1998-08-06 Lsr receptor, cloning and uses

Country Status (13)

Country Link
US (8) US6344441B1 (en)
EP (4) EP1003783B1 (en)
JP (3) JP2001512746A (en)
AT (3) ATE256146T1 (en)
AU (2) AU754942B2 (en)
CA (2) CA2298849A1 (en)
CY (1) CY1107808T1 (en)
DE (3) DE69820419T2 (en)
DK (2) DK0964870T3 (en)
ES (2) ES2210786T3 (en)
FR (1) FR2767135B1 (en)
PT (2) PT1003783E (en)
WO (2) WO1999007737A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469158B1 (en) * 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US6525174B1 (en) 1997-06-06 2003-02-25 Human Genome Sciences, Inc. Precerebellin-like protein
FR2767135B1 (en) 1997-08-06 2002-07-12 Genset Sa LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
WO2000026363A1 (en) * 1998-11-04 2000-05-11 Genset GENOMIC AND COMPLETE cDNA SEQUENCES OF HUMAN ADIPOCYTE-SPECIFIC APM1 AND BIALLELIC MARKERS THEREOF
WO2000047772A2 (en) 1999-02-10 2000-08-17 Genset Polymorphic markers of the lsr gene
MXPA01010540A (en) * 1999-04-20 2002-06-04 Zymogenetics Inc Adipocyte complement related protein homolog zacrp2.
AU4468800A (en) * 1999-04-20 2000-11-02 Zymogenetics Inc. Adipocyte complement related protein homolog zacrp3
CA2388417A1 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
WO2001032868A1 (en) * 1999-11-04 2001-05-10 Genset Apm1 biallelic markers and uses thereof
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
ATE405655T1 (en) * 2000-01-14 2008-09-15 Serono Genetics Inst Sa OBG3 GLOBULAR HEAD AND ITS USES FOR REDUCING BODY WEIGHT
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
WO2001092330A2 (en) * 2000-05-31 2001-12-06 Genset S.A. Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation
IL153927A0 (en) * 2000-07-18 2003-07-31 Genset Sa Genomic maps comprising biallelic markers, new such markers and the use of biallelic markers
MXPA03007672A (en) * 2001-02-26 2004-11-12 Univ Sydney Method of improving the growth performance of an animal.
US20020132773A1 (en) * 2001-03-14 2002-09-19 Oklahoma Medical Research Foundation Methods for reducing fat by administration of adiponectin
JP4547696B2 (en) * 2001-06-07 2010-09-22 第一三共株式会社 Cirrhosis prevention / treatment agent
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1418934A1 (en) * 2001-08-02 2004-05-19 Genset S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
WO2003041738A1 (en) * 2001-11-15 2003-05-22 Genset S.A. Treatment of metabolic disorders with xitar agonists and antagonists
AU2002339691A1 (en) * 2001-11-29 2003-06-10 Genset Agonists and antagonists of prolixin for the treatment of metabolic disorders
CA2473781A1 (en) * 2002-01-18 2003-07-31 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
US6852693B2 (en) 2002-02-07 2005-02-08 Blm Group Compositions and methods for promoting lipid mobilization in humans
US7419955B2 (en) * 2002-05-24 2008-09-02 Japan Science And Technology Agency Method for treating arteriosclerosis
US7459433B2 (en) 2002-05-31 2008-12-02 Serono Genetics Institute, S.A. Homotrimeric extended OBG3 globular head and uses thereof
WO2004063711A2 (en) * 2003-01-09 2004-07-29 Beth Israel Deaconess Medical Center, Inc. Use of adiponectin to diagnose and treat malignancy
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US8585771B2 (en) 2004-02-26 2013-11-19 Endosphere, Inc. Methods and devices to curb appetite and/or to reduce food intake
US7931693B2 (en) * 2004-02-26 2011-04-26 Endosphere, Inc. Method and apparatus for reducing obesity
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
EP1830873A4 (en) * 2004-12-10 2008-04-02 Protemix Corp Ltd GLYPONECTIN (ADIPONECTIN GLYCOSYLE) FOR THE TREATMENT OF DISEASES AND CONDITIONS
US7592423B2 (en) * 2005-01-07 2009-09-22 Xencor, Inc. Globular adiponectin variants
US7749956B2 (en) * 2005-01-07 2010-07-06 Xencor, Inc. Method of treatment using adiponectin variants
US7678886B2 (en) * 2005-01-07 2010-03-16 Xencor, Inc. Pharmaceutical compositions of adiponectin variants and methods of storage
JP2008526885A (en) * 2005-01-07 2008-07-24 ゼンコア Adiponectin mutant
US7964557B2 (en) * 2005-03-28 2011-06-21 University Of Louisville Research Foundation, Inc. Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30
US20070054359A1 (en) * 2005-07-11 2007-03-08 Jonathan Zalevsky Rational Chemical Modification of Adiponectin Variants
CA2616912A1 (en) * 2005-07-29 2007-02-08 Laboratoires Serono S.A. Use of the globular domain of acrp30 for the preparation of a medicament for the prevention and/or treatment of thrombosis-related diseases
US9060835B2 (en) 2006-05-26 2015-06-23 Endosphere, Inc. Conformationally-stabilized intraluminal device for medical applications
US20110137227A1 (en) 2007-07-16 2011-06-09 Mckinley James T Methods and devices for delivering or delaying lipids within a duodenum
JP5242701B2 (en) * 2007-12-19 2013-07-24 イーライ リリー アンド カンパニー Method for predicting responsiveness to drug therapy for obesity
JP5429736B2 (en) * 2009-04-13 2014-02-26 国立大学法人神戸大学 Tight junction regulator
MX363465B (en) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Treatment of submental fat.
NZ713461A (en) 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
IN2014KN00920A (en) * 2012-06-21 2015-10-09 Compugen Ltd
CN104004066B (en) * 2013-02-26 2017-05-31 上海市第一人民医院 Prevention suppresses inflammatory reaction and micromolecule polypeptide and its application of angiogenesis
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
US10174111B2 (en) 2013-12-27 2019-01-08 National University Corporation Kochi University Therapeutic drug for malignant tumors
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN120643715A (en) * 2025-06-16 2025-09-16 滨州医学院 Application of macrophage Angulin-1 in preparing medicine for preventing and/or treating atherosclerosis and related diseases and diagnostic product

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030400A1 (en) * 1995-03-24 1996-10-03 Tanox Biosystems, Inc. THE gC1q RECEPTOR, HIV-1 gp120 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODIES
WO1996039429A2 (en) * 1995-06-05 1996-12-12 Whitehead Institute For Biomedical Research Serum protein produced exclusively in adipocytes

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US77051A (en) * 1868-04-21 peters
US67881A (en) * 1867-08-20 Geobge p
US111500A (en) * 1871-01-31 Improvement in repeating fire-arms
US5543394A (en) * 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
NL9100132A (en) * 1991-01-25 1992-08-17 Ingeny Bv METHOD FOR DETECTING DNA SEQUENCE VARIATION.
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
FR2733762B1 (en) 1995-05-02 1997-08-01 Genset Sa METHOD FOR THE SPECIFIC COUPLING OF THE HAIR OF THE 5 'END OF A RNAM FRAGMENT AND PREPARATION OF RNAM AND COMPLETE DNA
WO1997027286A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US6116126A (en) 1996-07-10 2000-09-12 Van Den Bulcke; Marc Method and machine for making profile pieces
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO1998020165A2 (en) 1996-11-06 1998-05-14 Whitehead Institute For Biomedical Research Biallelic markers
HUP0003762A3 (en) * 1997-07-18 2005-11-28 Zymogenetics Inc Adipocyte-specific protein homologs
FR2767135B1 (en) * 1997-08-06 2002-07-12 Genset Sa LSR COMPLEX RECEPTOR, ACTIVITY, CLONING, AND APPLICATION TO DIAGNOSIS, PREVENTION AND / OR TREATMENT OF OBESITY AND THE RISKS OR COMPLICATIONS THEREOF
WO1999010492A1 (en) 1997-08-26 1999-03-04 Zymogenetics, Inc. Adipocyte-specific protein homologs
JP3538711B2 (en) * 1997-10-29 2004-06-14 大塚製薬株式会社 Smooth muscle proliferation inhibitory composition, arteriosclerosis diagnostic method and kit
US6579852B2 (en) 2000-01-14 2003-06-17 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030215836A1 (en) 2000-03-17 2003-11-20 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
WO2003011324A1 (en) 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1418934A1 (en) 2001-08-02 2004-05-19 Genset S.A. Xobesin agonists and antagonists for the treatment of metabolic disorders
AU2002339691A1 (en) 2001-11-29 2003-06-10 Genset Agonists and antagonists of prolixin for the treatment of metabolic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030400A1 (en) * 1995-03-24 1996-10-03 Tanox Biosystems, Inc. THE gC1q RECEPTOR, HIV-1 gp120 REGION BINDING THERETO, AND RELATED PEPTIDES AND TARGETING ANTIBODIES
WO1996039429A2 (en) * 1995-06-05 1996-12-12 Whitehead Institute For Biomedical Research Serum protein produced exclusively in adipocytes

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BIHAIN BE ET AL: "The lipolysis-stimulated receptor: a gene at last", CURRENT OPINION IN LIPODOLOGY, vol. 9, no. 3, June 1998 (1998-06-01), london gb, pages 221 - 224, XP002096548 *
GHEBREHIWET ET AL.: "Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1Q", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 179, June 1994 (1994-06-01), NEW YORK US, pages 1809 - 1821, XP002067463 *
HAYWARD CP ET AL.: "The cDNA sequence of human endothelial cell multimerin.", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 270, no. 31, 1995, baltimore US, pages 18246 - 18251, XP002096545 *
HU E ET AL.: "AdipoQ is a novel adipose-specific gene dysregulated in obesity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 18, 1996, BALTIMORE US, pages 10697 - 10703, XP002096544 *
MAEDA K ET AL: "CNDA CLONING AND EXPRESSION OF A NOVEL ADIPOSE SPECIFIC COLLAGEN- LIKE FACTOR, APM1 (ADIPOSE MOST ABUNDANT GENE TRANSCRIPT)", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 221, April 1996 (1996-04-01), pages 286 - 289, XP000612064 *
MANN C J ET AL.: "ApoCIII inhibits the binding of triglyceride-rich lipoproteins to the lipolysis stimulated receptor", CIRCULATION, vol. 94, no. 8,supp., 15 October 1996 (1996-10-15), US, pages I-698, XP002067462 *
MANN C J ET AL: "Mechanism of activation and fucntional significance of the lipolysis-stimulated receptor. Evidence for a role as chylomicron remnant receptor", BIOCHEMISTRY., vol. 34, 1995, EASTON, PA US, pages 10421 - 10431, XP002067468 *
SELLAR GC ET AL: "Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q", BIOCHEMICAL JOURNAL, vol. 274, 1 March 1991 (1991-03-01), pages 481 - 490, XP002087332 *
TROUSSARD AA ET AL.: "Inhibitory effect on the lipolysis-stimulated receptor of the 39-kda receptor-associated protein", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 270, no. 29, 1995, BALTIMORE US, pages 17068 - 17071, XP002096547 *
URADE Y ET AL.: "Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement C1q B chain", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 88, February 1991 (1991-02-01), WASHINGTON US, pages 1069 - 1073, XP002096546 *
WOODWARD F P ET AL (EDS): "Atherosclerosis X", 1995, ELSEVIER SCIENCE, AMSTERDAM NL, XP002067469 *

Also Published As

Publication number Publication date
AU745607B2 (en) 2002-03-21
CA2274302A1 (en) 1999-02-18
US20080249009A1 (en) 2008-10-09
EP1375516A3 (en) 2004-06-09
DE69841186D1 (en) 2009-11-05
DK0964870T3 (en) 2004-03-08
US6946444B2 (en) 2005-09-20
EP1903057A3 (en) 2008-06-25
US6635431B1 (en) 2003-10-21
EP1003783A2 (en) 2000-05-31
US20090263847A1 (en) 2009-10-22
US7220722B2 (en) 2007-05-22
US20040077051A1 (en) 2004-04-22
ATE378354T1 (en) 2007-11-15
JP2001512746A (en) 2001-08-28
JP2005143508A (en) 2005-06-09
DE69838720T2 (en) 2008-10-30
ES2296339T3 (en) 2008-04-16
US20020165154A1 (en) 2002-11-07
PT964870E (en) 2004-02-27
AU8556498A (en) 1999-03-01
ATE256146T1 (en) 2003-12-15
US20110165166A1 (en) 2011-07-07
JP3726969B2 (en) 2005-12-14
WO1999007737A2 (en) 1999-02-18
JP2001512492A (en) 2001-08-21
EP1375516A2 (en) 2004-01-02
EP0964870A2 (en) 1999-12-22
US7919091B2 (en) 2011-04-05
ES2210786T3 (en) 2004-07-01
EP0964870B1 (en) 2003-12-10
DE69838720D1 (en) 2007-12-27
US7291709B2 (en) 2007-11-06
EP1003783B1 (en) 2007-11-14
FR2767135A1 (en) 1999-02-12
DE69820419T2 (en) 2004-11-25
DE69820419D1 (en) 2004-01-22
CA2298849A1 (en) 1999-02-18
AU8556398A (en) 1999-03-01
WO1999007737A3 (en) 1999-06-10
DK1003783T3 (en) 2008-01-02
US6344441B1 (en) 2002-02-05
AU745607C (en) 2002-08-29
WO1999007736A2 (en) 1999-02-18
CY1107808T1 (en) 2013-06-19
EP1903057B1 (en) 2009-09-23
ATE443721T1 (en) 2009-10-15
AU754942B2 (en) 2002-11-28
EP1903057A2 (en) 2008-03-26
FR2767135B1 (en) 2002-07-12
US20020151498A1 (en) 2002-10-17
PT1003783E (en) 2007-12-06

Similar Documents

Publication Publication Date Title
WO1999007736A3 (en) Lipoprotein-regulating medicaments
AP1697A (en) Azabicycloalkanes as CCR5 modulators.
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
MXPA01008611A (en) Compounds and compositions for delivering active agents.
ZA905312B (en) Combination therapy for prohylaxsis and/or treatment of benign prostatic hyperplasia
PL331709A1 (en) Cytotoxic aminosaccharic and affinite saccharic derivatives of indolopyrrole carbazoles
DE69719798D1 (en) PERIPHERAL ADMINISTRATION OF GLP-1 ANALOGS AND DERIVATIVES FOR REGULATING OBESITY
MX9703186A (en) Indolyl neuropeptide y receptor antagonists.
TR199902253T2 (en) Controlled release of pharmaceuticals in the anterior chamber.
AP2001002187A0 (en) Piperidines as CCR5 modulators.
WO2002002077A3 (en) Liposomal antineoplastic drugs and uses thereof
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
AU2962295A (en) Cannabinoid receptor antagonists
IL153297A0 (en) Compounds and compositions for delivering active agents
MXPA03007857A (en) Compounds and compositions for delivering active agents.
CA2200195A1 (en) Use of aromatase inhibitors for the production of a pharmaceutical agentfor treating a relative androgen deficiency in men
ATE311373T1 (en) OXADIAZOLE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS
PL329802A1 (en) Derivatives of androstene
CA2270177A1 (en) Transdermal administration of ment
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
AU6469401A (en) Pharmaceutically active compounds and methods of use
CA2284142A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
NO20000519L (en) 2-acylaminopropanamines as tachykinin receptor antagonists
TR199903272T2 (en) New knowledge of asthma prescription drugs.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2298849

Country of ref document: CA

Ref country code: CA

Ref document number: 2298849

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09485316

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998936610

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 85563/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998936610

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 85563/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998936610

Country of ref document: EP